Akros Pharma Inc. clinical trials

Acquired by Shionogi, Dec 1, 2025 · source ↗

The registry lists 25 studies whose lead sponsor is Akros Pharma Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.

Studies

Recruiting first, then most recently updated. Showing 25 of 25. All Shionogi studies →

• Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)CompletedNCT07247266Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionCompletedNCT06017609Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 DiabetesCompletedNCT04465877Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03832738Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque PsoriasisTerminatedNCT03358290Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid ArthritisCompletedNCT02919475Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial HypertensionWithdrawnNCT03789643Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis SubjectsCompletedNCT03018509Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on HemodialysisCompletedNCT02805244Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal DiseaseCompletedNCT02581124Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252TerminatedNCT02120976Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic SubjectsCompletedNCT02106585Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal DiseaseCompletedNCT01971164Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal DiseaseCompletedNCT01978587Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes MellitusCompletedNCT01699737Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic PatientsCompletedNCT00929539Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Efficacy and Safety Study of JTT-654 in Type 2 Diabetic PatientsTerminatedNCT00997152Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety Study of JTT-302 in Subjects With Low HDL-C LevelsCompletedNCT00748852Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C LevelsCompletedNCT00749788Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy SubjectsCompletedNCT01475981Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy SubjectsTerminatedNCT01473069Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected SubjectsCompletedNCT01473056Phase 1

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsCompletedNCT00688558Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II HyperlipidemiaCompletedNCT00688896Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi

• Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsCompletedNCT00689442Phase 2

  Sponsor listed in the registry: Akros Pharma Inc. · First submitted before Akros Pharma Inc. became part of Shionogi